Pembrolizumab plus chemotherapy for pleural mesothelioma
| Errataetall: |
CommentOn: Lancet. 2023 Dec 16;402(10419):2295-2306. - PMID 37931632 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:402 |
|---|---|
| Enthalten in: |
Lancet (London, England) - 402(2023), 10419 vom: 16. Dez., Seite 2266-2267 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Y C Gary [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04Q9AIZ7NO |
|---|
| Anmerkungen: |
Date Completed 18.12.2023 Date Revised 07.02.2024 published: Print-Electronic CommentOn: Lancet. 2023 Dec 16;402(10419):2295-2306. - PMID 37931632 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0140-6736(23)01883-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364234369 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364234369 | ||
| 003 | DE-627 | ||
| 005 | 20240207232108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S0140-6736(23)01883-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM364234369 | ||
| 035 | |a (NLM)37931626 | ||
| 035 | |a (PII)S0140-6736(23)01883-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Y C Gary |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pembrolizumab plus chemotherapy for pleural mesothelioma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2023 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Lancet. 2023 Dec 16;402(10419):2295-2306. - PMID 37931632 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 650 | 7 | |a Pemetrexed |2 NLM | |
| 650 | 7 | |a 04Q9AIZ7NO |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Lancet (London, England) |d 1945 |g 402(2023), 10419 vom: 16. Dez., Seite 2266-2267 |w (DE-627)NLM000473936 |x 1474-547X |7 nnns |
| 773 | 1 | 8 | |g volume:402 |g year:2023 |g number:10419 |g day:16 |g month:12 |g pages:2266-2267 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0140-6736(23)01883-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 402 |j 2023 |e 10419 |b 16 |c 12 |h 2266-2267 | ||